Welcome to our dedicated page for Alx Oncology Holdings news (Ticker: ALXO), a resource for investors and traders seeking the latest updates and insights on Alx Oncology Holdings stock.
ALX Oncology Holdings Inc. (Nasdaq: ALXO) is a clinical-stage biotechnology company whose news flow centers on the development of investigational cancer therapies. The company regularly issues updates on its lead CD47 inhibitor, evorpacept, and its EGFR-targeted antibody-drug conjugate, ALX2004, as these programs advance through clinical and preclinical milestones.
News about ALX Oncology often covers clinical trial progress for evorpacept in HER2-positive gastric and gastroesophageal cancers, HER2-positive metastatic breast cancer and indolent B-cell non-Hodgkin lymphoma. Press releases detail study designs, enrollment status, biomarker findings such as CD47 overexpression as a potential predictive biomarker, and data presented at major oncology and immunotherapy conferences, including meetings of the Society for Immunotherapy of Cancer (SITC), the American Society of Hematology (ASH) and the European Society for Medical Oncology (ESMO).
For ALX2004, company announcements highlight preclinical data, poster presentations at scientific conferences such as the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, and updates from the ongoing Phase 1 first-in-human trial in EGFR-expressing solid tumors. These items typically describe dose-escalation progress, safety observations and the rationale for further clinical evaluation.
ALX Oncology also reports quarterly financial results and corporate updates via press releases and related conference calls, which are referenced in Current Reports on Form 8-K. Additional news may include participation in investor conferences, webcasts, and changes in leadership or board composition. Readers who follow ALXO news can use this page to track clinical milestones, data disclosures and corporate developments over time.
ALX Oncology (Nasdaq: ALXO) priced an underwritten offering to sell 76,979,112 shares of common stock and pre-funded warrants for 18,574,120 shares at $1.57 per share (pre-funded warrant price $1.569).
The offering is expected to close on or about Feb 2, 2026, with gross proceeds of approximately $150 million before expenses. Net proceeds are to fund continued clinical development of evorpacept and the ALX2004 program and for general corporate purposes.
ALX Oncology (Nasdaq: ALXO) reported exploratory Phase 1b/2 data showing CD47 expression predicts response to investigational CD47 inhibitor evorpacept combined with Ziihera (zanidatamab-hrii) in HER2-positive metastatic breast cancer. In nine centrally confirmed HER2-positive patients the combination produced a 56% confirmed objective response rate and median PFS of 7.4 months. The full biomarker analysis has been submitted for presentation at an upcoming scientific congress and reinforces prior ASPEN-06 gastric cancer findings linking CD47 expression to benefit.
ALX Oncology (Nasdaq: ALXO) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. Chief Executive Officer Jason Lettmann and Chief Medical Officer Barbara Klencke will deliver a corporate presentation and fireside chat on January 15, 2026 at 12:00 p.m. PT. A live webcast will be available via the Investors section of ALX Oncology’s website under Events and Presentations. A replay of the webcast will be archived and available for up to 90 days after the fireside chat.
ALX Oncology (Nasdaq: ALXO) announced clinical progress for two investigational therapies. The company dosed the first patient in the Phase 2 ASPEN-09-Breast trial of evorpacept combined with trastuzumab and physician’s choice chemotherapy in HER2-positive metastatic breast cancer post-ENHERTU; an interim analysis is anticipated in Q3 2026. The Phase 1 study of EGFR-targeted ADC ALX2004 advanced to a third dose cohort at 4 mg/kg after no dose-limiting toxicities in the first two cohorts; an initial safety update is expected in 1H 2026.
The ASPEN-09 trial will enroll ~80 patients and use CD47 expression and HER2 ctDNA as biomarkers; primary endpoint is overall response rate (ORR).
ALX Oncology (NASDAQ: ALXO) reported positive Phase 2 investigator‑sponsored data for evorpacept combined with rituximab and lenalidomide (R2) in untreated indolent B‑cell non‑Hodgkin lymphoma presented at ASH 2025.
In 24 frontline patients (14 follicular, 10 marginal zone), the regimen met its primary objective: 92% complete response (CR), 8% partial response, 100% overall response rate, one‑year PFS 91% and one‑year OS 100%. Investigators reported the combination was well tolerated; MRD evaluation and longer follow‑up were noted as next steps.
ALX Oncology (Nasdaq: ALXO) announced management will present at two investor conferences: a fireside chat at the Jefferies Global Healthcare Conference in London on Nov 19, 2025 at 11:30 AM GMT / 6:30 AM EST, and a fireside chat at the Piper Sandler 37th Annual Global Healthcare Conference in New York on Dec 3, 2025 at 9:30 AM EST.
Both events will be webcast; live links are available in the Investors > Events and Presentations section at www.alxoncology.com. Replays of each webcast will be archived for up to 90 days after the presentation dates.
ALX Oncology (Nasdaq: ALXO) reported Q3 2025 results and a corporate update on Nov 7, 2025. Key clinical highlights from an ASPEN-06 exploratory analysis showed strong benefit for evorpacept in retained HER2-positive, CD47-high gastric cancer: ORR 65.0% vs 26.1%, median DOR 25.5 vs 8.4 months, PFS 18.4 vs 7.0 months (HR 0.39), and OS 17.0 vs 9.9 months (HR 0.63).
ALX remains on track to start Phase 2 ASPEN-09-Breast Cancer enrollment in Q4 2025 with interim data expected Q3 2026. Phase 1 ALX2004 is enrolling (dose cohort 2 at 2 mg/kg) with initial safety data expected in 1H 2026. Q3 cash, cash equivalents and investments were $66.5 million, funding operations into Q1 2027. The company appointed Barbara Klencke, M.D., as interim CMO and will host a webcast on Nov 7, 2025.
ALX Oncology (Nasdaq: ALXO) will report third quarter 2025 financial results and provide a business update on Friday, November 7, 2025 before market open, followed by a teleconference and live webcast at 5:30 a.m. PT / 8:30 a.m. ET.
The company said it will review upcoming data presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting highlighting a full data set showing CD47 overexpression as a potential predictive biomarker for response to evorpacept in HER2-positive gastric/gastroesophageal cancer. A poster (abstract 496) will be presented at SITC on November 8, 2025 and available as an eposter on November 7; presenter: Dr. Zev A. Wainberg.
Webcast and archived replay will be available on the company investor website.
ALX Oncology (NASDAQ: ALXO) presented preclinical data and the Phase 1 trial design for ALX2004, an EGFR-targeted antibody-drug conjugate, at the 2025 AACR-NCI-EORTC conference on October 23, 2025.
The company reported a robust preclinical package supporting differentiation in the EGFR-ADC class, described ALX2004’s matuzumab-derived EGFR antibody, proprietary Top1i payload and linker designed to improve on-target delivery and bystander effect, and confirmed the ongoing first-in-human study (NCT07085091) for advanced/metastatic EGFR-expressing solid tumors.
Enrollment began in August 2025 and initial safety data is anticipated in H1 2026.
ALX Oncology (Nasdaq: ALXO) will present updated Phase 2 ASPEN-06 data at the SITC 40th Annual Meeting (Nov 5–9, 2025) in National Harbor, MD. The poster reports that CD47 expression is a predictive biomarker for response to evorpacept in previously treated HER2-positive gastric and gastroesophageal junction cancer.
ASPEN-06 tested evorpacept combined with trastuzumab, ramucirumab, and paclitaxel. Poster details: Title "CD47 expression as a predictive biomarker for evorpacept in HER2-positive gastric/gastroesophageal cancer from the Phase 2 randomized ASPEN-06 trial," First Author Zev A. Wainberg, M.D., Abstract 496, presented Saturday, November 8, 2025, 10:00 a.m.–6:35 p.m. ET in Poster Hall (Exhibit Halls AB).
FAQ
What is the current stock price of Alx Oncology Holdings (ALXO)?
What is the market cap of Alx Oncology Holdings (ALXO)?
